Enanta Pharm (ENTA) Narrows Q2 Loss

Enanta Pharm (NASDAQ: ENTA) reported Q2 EPS of ($0.28), versus ($2.28) reported last year. Revenue for the quarter came in at $2.2 million, versus $1.2 million reported last year.

For earnings history and earnings-related data on Enanta Pharm (ENTA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT